...
首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
【24h】

Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.

机译:维持治疗门静脉高压症的血液动力学反应,并影响肝硬化并发症。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND/AIMS: Following treatment with beta blockers in patients with cirrhosis and portal hypertension, reduction of hepatic venous pressure gradient (HVPG) to <12 mmHg or by >20% of baseline induces an extremely low risk of variceal bleeding. However, several factors such as compliance to therapy or alcohol abstinence may change the initial response after a long follow-up, and the effect of response on other complications of cirrhosis is less clear. The aim of this study was to assess the long-term maintenance of hemodynamic response and its influence on complications of cirrhosis. METHODS: One hundred and thirty two cirrhotic patients received nadolol and isosorbide mononitrate to prevent variceal rebleeding. HVPG was measured at baseline, after 1 to 3 months under treatment and again 12 to 18 months later. RESULTS: Sixty four patients were responders. After a longer follow-up, earlier response did not change in 81% of cases. Changes of response were mainly related to modifications in medication dose or in alcohol intake. As compared with poor-responders, responders had a lower probability of developing ascites (P<0.001) and related conditions, a greater improvement of Child-Pugh score (P=0.03), and a lower likelihood of developing encephalopathy (P=0.001) and of requiring liver transplantation (P=0.002). Eleven responders and 22 poor-responders died (P=0.029). CONCLUSIONS: Hemodynamic response to treatment of portal hypertension is usually sustained after a long-term follow-up. Response decreases the probability of developing complications of cirrhosis and the need for liver transplantation, and significantly improves survival.
机译:背景/目的:在肝硬化和门静脉高压症患者中使用β受体阻滞剂治疗后,将肝静脉压力梯度(HVPG)降低至<12 mmHg或基线的> 20%,可导致静脉曲张破裂出血的风险极低。但是,在长期随访后,如对治疗的依从性或戒酒等多种因素可能会改变初始反应,而该反应对肝硬化其他并发症的影响尚不清楚。这项研究的目的是评估血液动力学反应的长期维持及其对肝硬化并发症的影响。方法:132例肝硬化患者接受纳多洛尔和单硝酸异山梨酯预防静脉曲张再出血。在治疗后1到3个月,然后在12到18个月后,在基线时测量HVPG。结果:64例患者有反应。经过更长的随访,在81%的病例中,早期反应没有改变。反应的变化主要与药物剂量或饮酒量的变化有关。与反应较差的人相比,反应者发生腹水的可能性较低(P <0.001)和相关疾病,Child-Pugh评分的改善较大(P = 0.03),发生脑病的可能性较低(P = 0.001)并且需要进行肝移植(P = 0.002)。 11名响应者和22名响应不佳者死亡(P = 0.029)。结论:对门静脉高压症的血液动力学反应通常在长期随访后得以维持。反应降低了发生肝硬化并发症的可能性和对肝移植的需求,并显着提高了生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号